Consensus guidelines acknowledge the role of gallium Ga-68 (Ga) 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic (DOTA) somatostatin receptor (SSTR) positron emission tomography/computed tomography (PET/CT) in management of neuroendocrine tumor (NET) patients. Ga-DOTA-SSTR PET/CT demonstrates superior performance to conventional imaging in initial detection, staging, detection of recurrent tumor, and detection of unknown primary in known metastatic disease. Ga-DOTA-SSTR PET/CT is low yield for NET detection in the setting of symptoms or elevated biomarkers when conventional imaging is negative, but may still guide management. The role of Ga-DOTA-SSTR PET/CT is not established in monitoring response to systemic therapy but may identify progression through detection of new metastases.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7700750 | PMC |
| http://dx.doi.org/10.1016/j.soc.2019.11.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluación de la fiabilidad y legibilidad de las respuestas de los chatbots como recurso de información al paciente para las exploraciones PET-TC más communes.
Rev Esp Med Nucl Imagen Mol (Engl Ed)
September 2024
Department of Software Engineering, ASELSAN Inc., Ankara, Turkiye. Electronic address:
Purpose: This study aimed to evaluate the reliability and readability of responses generated by two popular AI-chatbots, 'ChatGPT-4.0' and 'Google Gemini', to potential patient questions about PET/CT scans.
Materials And Methods: Thirty potential questions for each of [F]FDG and [Ga]Ga-DOTA-SSTR PET/CT, and twenty-nine potential questions for [Ga]Ga-PSMA PET/CT were asked separately to ChatGPT-4 and Gemini in May 2024.
Clinical value of Ga-DOTA-SSTR PET/CT in the diagnosis and detection of neuroendocrine tumors of unknown primary origin: a systematic review and meta-analysis.
Acta Radiol
September 2021
Nuclear Medicine Department, Beijing Friendship Hospital of Capital Medical University, Beijing, PR China.
Background: The ability of Ga-DOTA-SSTR to detect the primary sites of neuroendocrine tumors (NETs) remains undetermined, and the clinical benefit of this imaging agent is not clear.
Purpose: To evaluate the diagnostic accuracy of Ga-DOTA-SSTR for carcinoma unknown primary (CUP) neuroendocrine tumors and to further analyze the detection rate of Ga-DOTA-SSTR for primary and metastatic sites.
Material And Methods: A comprehensive literature search of PubMed/MEDLINE and ScienceDirect was performed in October 2019 in accordance with the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) guidelines.
Nuclear Imaging of Neuroendocrine Tumors.
Surg Oncol Clin N Am
April 2020
Department of Radiology, Roy J. and Lucille A. Carver College of Medicine, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, IA 52242, USA.
Consensus guidelines acknowledge the role of gallium Ga-68 (Ga) 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic (DOTA) somatostatin receptor (SSTR) positron emission tomography/computed tomography (PET/CT) in management of neuroendocrine tumor (NET) patients. Ga-DOTA-SSTR PET/CT demonstrates superior performance to conventional imaging in initial detection, staging, detection of recurrent tumor, and detection of unknown primary in known metastatic disease. Ga-DOTA-SSTR PET/CT is low yield for NET detection in the setting of symptoms or elevated biomarkers when conventional imaging is negative, but may still guide management.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!